Streetbeat News

Stock Prices

VIPS

Vipshop Holdings Limited (NYSE:VIPS) shares surged after reporting Q4 adjusted earnings per ADS of 82 cents, beating the consensus of 71 cents, and revenues of $4.88 billion, exceeding expectations of $4.69 billion. Sales grew 9.2% YoY, driven by increased active customers and spending in discretionary categories. GMV and total orders saw significant increases, while gross profit rose 19.3% YoY. The company declared a dividend of $0.43 per ADS for FY2023 and provided a positive revenue outlook for Q1 2024.

Portfolio Pulse from Nabaparna Bhattacharya

February 28, 2024 | 5:11 pm

FLGT

Fulgent Genetics' stock price declined following the announcement of Q4 financial results and FY24 guidance that fell short of expectations.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 5:07 pm

LLY

NVO

VKTX

Viking Therapeutics Inc (NASDAQ:VKTX) released successful Phase 2 weight loss trial results for VK2735, showing significant reductions in body weight compared to placebo. The results outperformed Novo Nordisk A/S's (NYSE:NVO) and Eli Lilly And Co's (NYSE:LLY) similar trials. Viking also announced a $350 million capital raise. Analysts from HC Wainwright and William Blair highlighted VK2735's superior performance and revised its peak sales estimate upwards. VKTX shares rose 9.34% to $92.99.

Portfolio Pulse from Vandana Singh

February 28, 2024 | 5:05 pm

ASTE

Astec Industries' shares surged following the announcement of their Q4 adjusted EPS results, which exceeded expectations.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 5:05 pm

DAKT

Daktronics shares are trading higher following the announcement of their Q3 financial results.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 5:03 pm

QTRX

Quanterix (NASDAQ:QTRX) is scheduled to release its quarterly earnings report on Thursday, 2024-02-29, with an expected EPS of $-0.32. Analysts and investors are looking for an earnings beat and positive guidance for the next quarter. Historically, Quanterix has surpassed EPS estimates, leading to varying stock price reactions. The stock has seen a 115.35% increase over the last 52 weeks, indicating a bullish sentiment among long-term shareholders.

Portfolio Pulse from Benzinga Insights

February 28, 2024 | 5:02 pm

FDUS

Fidus Investment (NASDAQ:FDUS) is scheduled to release its quarterly earnings report on Thursday, 2024-02-29, with analysts expecting an EPS of $0.58. The company's past performance shows a pattern of beating EPS estimates, which has occasionally led to positive stock price movements the following day. Shares of FDUS were trading at $19.79 as of February 27, marking a 4.73% decline over the last 52 weeks. Investors are looking for not only an earnings beat but also positive guidance for the next quarter.

Portfolio Pulse from Benzinga Insights

February 28, 2024 | 5:02 pm

CAPR

Capricor Therapeutics (NASDAQ:CAPR) is expected to report a Q4 earnings per share (EPS) of $-0.09 on Thursday, 2024-02-29. Analysts and investors are looking for an earnings beat and positive guidance for the next quarter. Historically, Capricor has had mixed earnings performance, with share price reactions varying post-earnings announcement. Currently, shares are trading at $4.34, down 13.85% over the last 52 weeks.

Portfolio Pulse from Benzinga Insights

February 28, 2024 | 5:02 pm

CVEO

Civeo (NYSE:CVEO) is anticipated to report a quarterly EPS of $0.07 on Thursday, 2024-02-29. Analysts and investors are keen on whether Civeo will surpass this estimate and provide positive future guidance. Historical data shows mixed reactions in stock price to past earnings reports, with a notable 0.0% change after last quarter's beat. Currently, shares are trading at $22.32, marking a 3.41% decline over the last year, indicating investor concern ahead of the earnings release.

Portfolio Pulse from Benzinga Insights

February 28, 2024 | 5:01 pm

VRNA

Verona Pharma (NASDAQ:VRNA) is scheduled to release its quarterly earnings report on Thursday, 2024-02-29, with an expected EPS of $-0.26. Analysts and investors are keen on whether the company will surpass this estimate and provide positive guidance for the next quarter. Historical data shows a mixed reaction to past earnings reports, with the stock price fluctuating based on the actual EPS compared to estimates. Currently, VRNA shares are trading at $17.91, marking a 20.21% decrease over the last 52 weeks, indicating a bearish sentiment among long-term shareholders.

Portfolio Pulse from Benzinga Insights

February 28, 2024 | 5:01 pm